title: Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen.
abstract: Neuron-specific enolase (NSE) and carcinoembryonic antigen (CEA) have been reported to be useful markers for staging, monitoring treatment, and predicting relapse in patients with small cell lung cancer (SCLC). Recently, pro-gastrin-releasing peptide (Pro-GRP) became available as a sensitive, specific, and reliable tumor marker for patients with SCLC. The aim of this study is to determine the most useful tumor marker to detect the relapse of SCLC. Furthermore, we analyzed the relationship between tumor markers at relapse and survival from relapse or response to salvage chemotherapy. Medical records were reviewed to obtain serum levels of Pro-GRP, NSE, and CEA before and after the initial chemotherapy, and at relapse. Consecutive 66 patients with SCLC, with an objective response and confirmed relapse treated at the National Cancer Center Hospital East, were analyzed in this study. The percentages of patients whose tumor marker level were elevated before treatment, decreased after the treatment, and increased again at relapse were 67% (95% CI, 55-78) for Pro-GRP, 20% (10-29) for NSE, and 38% (26-50) for CEA. Multivariate analysis indicated that poor performance status before initial treatment and elevated serum levels of lactate dehydrogenase at relapse were poor prognostic factors for patients with recurrent SCLC (P<0.005). None of the serum levels of Pro-GRP, NSE, and CEA at relapse was a significant prognostic factor and associated with an objective response to salvage chemotherapy. The present study demonstrated that serum levels of Pro-GRP reflect the disease course of patients with SCLC most accurately.
authors.affiliation: Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwanoha 6-5-1, Kashiwa, Chiba, Japan. siniho@east.ncc.go.jp
authors.forename: S
authors.initials: S
authors.lastname: Niho
authors.forename: Y
authors.initials: Y
authors.lastname: Nishiwaki
authors.forename: K
authors.initials: K
authors.lastname: Goto
authors.forename: H
authors.initials: H
authors.lastname: Ohmatsu
authors.forename: T
authors.initials: T
authors.lastname: Matsumoto
authors.forename: F
authors.initials: F
authors.lastname: Hojo
authors.forename: Y
authors.initials: Y
authors.lastname: Ohe
authors.forename: R
authors.initials: R
authors.lastname: Kakinuma
authors.forename: T
authors.initials: T
authors.lastname: Kodama
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D018288:Carcinoma, Small Cell / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D010446:Peptide Fragments / Q000097:blood*; D010455:Peptides / Q000097:blood*; D010751:Phosphopyruvate Hydratase / Q000097:blood; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D011994:Recombinant Proteins / Q000097:blood; D012189:Retrospective Studies; D016879:Salvage Therapy; D012680:Sensitivity and Specificity; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D010446:Peptide Fragments; D010455:Peptides; D011994:Recombinant Proteins; C087079:pro-gastrin-releasing peptide (31-98); D010751:Phosphopyruvate Hydratase